JAMA: Tele-ICUs associated with better outcomes

Intensive care units (ICUs) that implemented telemedicine intervention including offsite electronic monitoring of processes and detection of nonadherence to best practices had lower hospital and ICU mortality, lower rates of preventable complications and shorter hospital and ICU length of stay, according to a study published May 16 online in the Journal of the American Medical Association.

To examine which tele-ICU-related process changes are associated with better outcomes, Craig M. Lilly, MD, of the University of Massachusetts Medical School in Worcester, and colleagues evaluated the association of a tele-ICU intervention with the risk of dying in the hospital and length of stay, and the relationship of best practice adherence and preventable complications to these outcomes.

The study, performed from April 2005 through September 2007, included 6,290 adults admitted to any of seven ICUs (three medical, three surgical and one mixed cardiovascular) on two campuses of an 834-bed academic medical center.

The offsite tele-ICU team included an intensivist and used tele-ICU workstations. Team responsibilities included reviewing the care of individual patients, performing real-time audits of best practice adherence, monitoring system-generated electronic alerts, auditing bedside clinician responses to in-room alarms and intervening when the responses of bedside clinicians were delayed and patients were deemed physiologically unstable. The offsite team could communicate with bedside clinicians or directly manage patients by recording clinician orders for tests, treatments, consultations and management of life-support devices.

After analyzing the data from the study period, the researchers found that the hospital mortality rate was 13.6 percent during the preintervention period compared with 11.8 percent during the tele-ICU intervention. The ICU mortality rate was 10.7 percent for the preintervention group and 8.6 percent for the tele-ICU group. The length of hospital stay was 13.3 days in the preintervention group and 9.8 days in the tele-ICU group, and length of ICU stay was 6.4 days in the preintervention group and 4.5 days in the tele-ICU group, wrote Lilly and colleagues.

The tele-ICU intervention period compared with the preintervention period was associated with higher rates of best clinical practice adherence for the prevention of deep vein thrombosis (99 percent vs. 85 percent), prevention of stress ulcers (96 percent vs. 83 percent), best practice adherence for cardiovascular protection (99 percent vs. 80 percent), prevention of ventilator-associated pneumonia (52 percent vs. 33 percent) and lower rates of preventable complications (1.6 percent vs. 13 percent for ventilator-associated pneumonia and 0.6 percent vs. 1.0 percent for catheter-related blood stream infection). The results for medical, surgical and cardiovascular ICUs were similar, the researchers stated.

For the tele-ICU group compared with the preintervention group, the fraction of patients requiring mechanical ventilation was significantly lower and the duration of mechanical ventilation was significantly shorter. Also, patients in the tele-ICU group were 8 percent more likely to go home, 6 percent less likely to go to rehabilitation or to a long-term care facility and 2 percent more likely to go to a skilled nursing facility than patients in the preintervention group.

“An adult tele-ICU intervention at an academic medical center that had been previously well staffed with a dedicated intensivist model and had robust best practice programs in place before the intervention was associated with lower mortality and shorter lengths of stay,” the authors concluded. “Only part of these associations could be attributed to following best practice guidelines and lower rates of preventable complications. This suggests that there are benefits of a tele-ICU intervention beyond what is provided by daytime bedside intensivist staffing and traditional approaches to quality improvement.”

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.